Vertex Reports Fiscal-Year Growth And Price Target Raises

Vertex Pharmaceuticals reported fiscal Q4 and full-year 2025 results on February 12, posting $12.0 billion in full-year revenue, up 9%, and Q4 revenue of $3.19 billion, up 10% year-over-year. Following the results, analysts on February 17 raised price targets — Canaccord to $441, Barclays to $607, H.C. Wainwright to $591 — citing continued commercial strength and pipeline progress.